###begin article-title 0
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GnRH </italic>
###xml 9 13 9 13 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LHR </italic>
###xml 82 90 <span type="species:ncbi:9606">patients</span>
GnRH and LHR gene variants predict adverse outcome in premenopausal breast cancer patients
###end article-title 0
###begin p 1
This is an open access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 95 100 <span type="species:ncbi:9606">women</span>
Breast cancer development and progression are dependent on estrogen activity. In premenopausal women, estrogen production is mainly regulated through the hypothalamic-pituitary-gonadal (HPG) axis.
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
###xml 104 109 104 109 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GnRH </italic>
###xml 151 161 151 161 <italic xmlns:xlink="http://www.w3.org/1999/xlink">16Trp/Ser </italic>
###xml 178 182 178 182 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LHR </italic>
###xml 226 232 226 232 <italic xmlns:xlink="http://www.w3.org/1999/xlink">insLQ </italic>
###xml 298 306 <span type="species:ncbi:9606">patients</span>
###xml 370 378 <span type="species:ncbi:9606">patients</span>
We have investigated the prognostic significance of two variants of genes involved in the HPG-axis, the GnRH (encoding gonadotropin-releasing hormone) 16Trp/Ser genotype and the LHR (encoding the luteinizing hormone receptor) insLQ variant, in retrospectively collected premenopausal breast cancer patients with a long follow-up (median follow-up of 11 years for living patients).
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
###xml 189 199 189 199 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LHR insLQ </italic>
###xml 203 214 203 214 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GnRH 16Ser </italic>
###xml 386 397 386 397 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GnRH 16Ser </italic>
###xml 401 411 401 411 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LHR insLQ </italic>
###xml 600 602 600 602 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 328 336 <span type="species:ncbi:9606">patients</span>
###xml 359 367 <span type="species:ncbi:9606">patients</span>
Carriership was not related with breast cancer risk (the case control study encompassed 278 premenopausal cases and 1,758 premenopausal controls). A significant adverse relationship of the LHR insLQ and GnRH 16Ser genotype with disease free survival (DFS) was observed in premenopausal (hormone receptor positive) breast cancer patients. In particular, those patients carrying both the GnRH 16Ser and LHR insLQ allele (approximately 25%) showed a significant increased risk of relapse, which was independent of traditional prognostic factors (hazard ratio 2.14; 95% confidence interval 1.32 to 3.45; P = 0.002).
###end p 7
###begin title 8
Conclusion
###end title 8
###begin p 9
###xml 21 31 21 31 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LHR insLQ </italic>
###xml 35 46 35 46 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GnRH 16Ser </italic>
###xml 117 125 <span type="species:ncbi:9606">patients</span>
###xml 236 244 <span type="species:ncbi:9606">patients</span>
We conclude that the LHR insLQ and GnRH 16Ser alleles are independently associated with shorter DFS in premenopausal patients. When validated, these findings may provide a lead in the development of tailored treatment for breast cancer patients carrying both polymorphisms.
###end p 9
###begin title 10
Introduction
###end title 10
###begin p 11
###xml 225 226 225 226 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 227 228 227 228 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 389 390 389 390 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 391 392 391 392 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 608 609 608 609 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 610 611 610 611 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 813 814 813 814 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 815 816 815 816 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 105 110 <span type="species:ncbi:9606">women</span>
###xml 218 223 <span type="species:ncbi:9606">women</span>
###xml 328 333 <span type="species:ncbi:9606">women</span>
The diagnosis of breast cancer is made one million times each year worldwide. About one-quarter of these women are premenopausal at time of diagnosis, which is associated with poor prognosis compared to postmenopausal women [1,2]. It is anticipated that, as a result of changing demographic and lifestyle factors, more and more women will be diagnosed at a younger age with breast cancer [3,4]. In addition to age and family history, several factors relating to increased or prolonged cumulative estrogen exposure have been identified as important risk factors for breast cancer development and progression [5,6]. Polymorphic variation in genes regulating estrogen production may partly explain differences in susceptibility, clinical presentation and outcome of breast cancer between individuals or populations [6,7].
###end p 11
###begin p 12
###xml 489 497 489 497 <italic xmlns:xlink="http://www.w3.org/1999/xlink">de novo </italic>
###xml 1375 1376 1375 1376 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 1377 1378 1377 1378 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 17 22 <span type="species:ncbi:9606">women</span>
###xml 628 633 <span type="species:ncbi:9606">women</span>
In premenopausal women, estrogens predominantly arise from the ovaries, where production is regulated by the neuro-endocrine system consisting of hypothalamus, pituitary and gonads: the HPG axis. Internal and external stimuli are integrated in the brain, resulting in the pulsatile secretion of the hypothalamic neuropeptide gonadotropin-releasing hormone (GnRH). GnRH reaches the gonadotroph cells in the anterior pituitary through the hypophysial portal circulation, where it stimulates de novo synthesis and secretion of the gonadotropins follicle stimulating hormone and luteinizing hormone (LH), which reach the ovaries in women through the circulation. LH, acting through the LH receptor (LHR), stimulates production of androgen precursors in theca cells that surround antral follicles. Follicle stimulating hormone subsequently regulates the granulosa cell enzyme aromatase, which converts these androgens to estrogens. In turn, ovarian sex steroid and peptide hormones (inhibin A and B) provide negative feedback regulation, either in the pituitary or hypothalamus. The menopausal transition, that is, the cessation of menstrual cycling, is characterized by disruption of this tightly balanced HPG axis system and is accompanied by continuously increased serum LH and follicle stimulating hormone in combination with decreased levels of ovarian sex steroid hormones [8,9].
###end p 12
###begin p 13
###xml 166 175 166 175 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LHR insLQ</italic>
###xml 206 210 206 210 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LHR </italic>
###xml 234 236 234 236 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 539 549 539 549 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LHR insLQ </italic>
###xml 606 608 606 608 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 940 950 940 950 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LHR insLQ </italic>
###xml 960 962 960 962 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 984 989 984 989 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GnRH </italic>
###xml 1056 1058 1056 1058 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 1164 1166 1164 1166 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 79 87 <span type="species:ncbi:9606">patients</span>
###xml 459 467 <span type="species:ncbi:9606">patients</span>
###xml 922 930 <span type="species:ncbi:9606">patients</span>
We have previously reported, in a training set of 266 Australian breast cancer patients, an association between a common polymorphic CTCCAG (Leu-Gln (LQ)) insertion (LHR insLQ) in the signal peptide of the LHR gene and poor survival [10]. No associations between its ligand, LH, genotype and clinical parameters were observed in this study. In our subsequent validation study on a large independent breast cancer cohort of 751 retrospectively collected Dutch patients with long detailed follow-up, we have confirmed the association of the LHR insLQ gene variant with a shorter disease-free survival (DFS) [11]. Furthermore, we have shown the functional importance of the LQ insertion in the signal peptide, that is, an increased activity for the LHR insLQ variant compared with the LHR non-LQ protein. We hypothesized an ovary-dependent increase in cumulative estrogen exposure that may influence breast cancer outcome in patients with the LHR insLQ genotype [10]. Interestingly, the GnRH gene also carries a common signal peptide polymorphism (Trp16Ser) [12], which has been associated with altered bone mineral density, an indirect marker for estrogen exposure [13].
###end p 13
###begin p 14
###xml 198 208 198 208 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LHR insLQ </italic>
###xml 212 223 212 223 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GnRH 16Ser </italic>
In line with the hypothesis that possible associations of the above mentioned polymorphisms with outcome would depend on HPG-regulation of ovarian function, we have investigated associations of the LHR insLQ and GnRH 16Ser alleles with premenopausal breast cancer outcome in the present study.
###end p 14
###begin p 15
###xml 179 189 179 189 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LHR insLQ </italic>
###xml 57 62 <span type="species:ncbi:9606">women</span>
We observed that hormone receptor positive premenopausal women carrying either of the variant alleles or the combined variant alleles of both genes had a significant shorter DFS; LHR insLQ and the combined alleles were independent of traditional prognostic factors.
###end p 15
###begin title 16
Materials and methods
###end title 16
###begin title 17
Breast tumor samples
###end title 17
###begin p 18
###xml 176 178 176 178 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 359 367 359 367 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in situ </italic>
###xml 216 224 <span type="species:ncbi:9606">patients</span>
The study design was approved by the Medical Ethics Committee of the Erasmus MC, Rotterdam, the Netherlands. From the DNA samples with complete follow up described previously [11], we have included 278 premenopausal patients with known estrogen receptor (ER) status, conclusive genotypes and complete follow up. All tumors were invasive (42 had an additional in situ component).
###end p 18
###begin p 19
###xml 602 603 602 603 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 25 33 <span type="species:ncbi:9606">patients</span>
###xml 169 177 <span type="species:ncbi:9606">patients</span>
###xml 263 271 <span type="species:ncbi:9606">patients</span>
###xml 331 339 <span type="species:ncbi:9606">patients</span>
###xml 558 565 <span type="species:ncbi:9606">patient</span>
The menopausal status of patients was determined according to the guidelines of the European Organization of Research and Treatment of Cancer (EORTC). The median age of patients at diagnosis was 45 years (range 22 to 57 years). The median follow-up period of all patients was 112 months (range 9 to 255 months) and of still living patients 130 months from primary surgery (range 13 to 255 months). Pathological examination was not performed centrally and reflects daily practice in the various participating regional hospitals as described previously. Other patient characteristics are listed in Table 1.
###end p 19
###begin p 20
###xml 68 78 68 78 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LHR insLQ </italic>
###xml 82 93 82 93 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GnRH 16Ser </italic>
###xml 46 54 <span type="species:ncbi:9606">patients</span>
Baseline characteristics in 278 premenopausal patients according to LHR insLQ and GnRH 16Ser carriership
###end p 20
###begin p 21
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 4 6 2 4 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 12 13 10 11 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
###xml 51 53 49 51 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 62 63 60 61 <sup xmlns:xlink="http://www.w3.org/1999/xlink">c</sup>
###xml 171 172 169 170 <sup xmlns:xlink="http://www.w3.org/1999/xlink">d</sup>
###xml 196 198 194 196 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 238 239 236 237 <sup xmlns:xlink="http://www.w3.org/1999/xlink">e</sup>
###xml 285 286 283 284 <sup xmlns:xlink="http://www.w3.org/1999/xlink">f</sup>
###xml 330 332 328 330 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
achi2 test. bAlso, when stratified per 'genotype', P = 0.003. cNumbers in cells may not add up due to incomplete information on histological grade and/or receptor status. dTumors of unknown size (n = 10) are included as tumor size >2 cm. eThe cutoff value used was 10 fmol/mg protein. fSignificant when stratified per 'genotype', P = 0.02. Entries in bold represent significant outcomes.
###end p 21
###begin title 22
Control population
###end title 22
###begin p 23
###xml 423 425 423 425 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 638 642 638 642 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LHR </italic>
###xml 653 658 653 658 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GnRH </italic>
###xml 79 84 <span type="species:ncbi:9606">women</span>
###xml 230 235 <span type="species:ncbi:9606">women</span>
###xml 428 440 <span type="species:ncbi:9606">Participants</span>
###xml 719 724 <span type="species:ncbi:9606">women</span>
As a control cohort we studied banked blood samples of pre- and perimenopausal women from the Eindhoven Perimenopausal Osteoporosis Study (EPOS). The EPOS study is a population-based cohort study of pre-, peri- and postmenopausal women born between 1941 and 1947 living in the city of Eindhoven, The Netherlands (median age 50.0 years (range 46 to 57 years)). The study rationale and design have been described previously [14]. Participants gave their written informed consent, and the study was approved by the Medical Ethics Committee of the Erasmus MC, Rotterdam. For the present study we included 1,758 (successful genotyping for the LHR as well as GnRH genotypes) pre- and perimenopausal subjects, after excluding women with a history of breast carcinoma. All subjects (median age 49.5 years) are of Caucasian Dutch descent. Data for baseline examination and blood samples for extracting DNA from peripheral leucocytes were collected between 1994 and 1995.
###end p 23
###begin title 24
Genotyping
###end title 24
###begin p 25
###xml 94 98 94 98 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LHR </italic>
###xml 155 157 155 157 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 277 287 277 287 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LHR insLQ </italic>
###xml 521 523 521 523 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
High molecular weight genomic DNA was used as a template for PCR amplification. Exon 1 of the LHR gene was amplified as described by Atger and colleagues [15] using a 5'-hexachlorofluorescein labeled forward primer. Separation and sizing of the PCR fragments and assignment of LHR insLQ genotype was performed using the ABI Prism 3100 automated capillary DNA sequencer and Genescan and Genotyper software packages (Applied Biosystems, Perkin Elmer, Nieuwerkerk aan den IJssel, The Netherlands) as described by us before [11].
###end p 25
###begin p 26
###xml 4 14 4 14 <italic xmlns:xlink="http://www.w3.org/1999/xlink">16Trp/Ser </italic>
###xml 34 39 34 39 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GnRH </italic>
###xml 354 355 354 355 <underline xmlns:xlink="http://www.w3.org/1999/xlink">C</underline>
###xml 392 393 392 393 <underline xmlns:xlink="http://www.w3.org/1999/xlink">G</underline>
###xml 535 537 535 537 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 924 926 924 926 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
The 16Trp/Ser polymorphism in the GnRH gene was determined using the Taqman allelic discrimination assay. Primer sequences used for amplification of the fragment of exon 1, including the single nucleotide polymorphism (SNP) were AATTCAAAAACTCCTAGCTGGCCTTA (forward) and CATAGGACCAGTGCTGGCT (reverse). Used probes (with SNP underlined) were 5'-VIC-CACGCACCAAGTCA (anti-sense) and 5'-FAM-AGCCACGAAGTCA (anti-sense). Primer and probe sequences were optimized using the SNP assay-by-design service of Applied Biosystems (for details, see [16]). These reactions were performed on the Taqman Prism 7900 HT 384 wells format. Snap frozen primary breast cancer specimens, stored in liquid nitrogen and from which the DNA was obtained for genotyping, contain a relatively high proportion (>40%) of non-tumor tissue. This ensures accurate genotyping, irrespective of the possible loss of heterozygosity that may occur in tumor tissue [10]. Furthermore, to test for possible loss of heterozygosity we have examined the Hardy-Weinberg equilibrium (HWE).
###end p 26
###begin title 27
Statistical analysis
###end title 27
###begin p 28
###xml 13 15 11 13 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 512 513 508 509 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 538 540 534 536 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 650 652 644 646 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 914 924 908 918 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LHR insLQ </italic>
###xml 928 939 922 933 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GnRH 16Ser </italic>
###xml 1030 1040 1024 1034 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LHR insLQ </italic>
###xml 1044 1055 1038 1049 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GnRH 16Ser </italic>
###xml 1573 1575 1565 1567 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 1814 1816 1806 1808 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 1826 1828 1816 1818 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 138 145 <span type="species:ncbi:9606">patient</span>
###xml 258 265 <span type="species:ncbi:9606">patient</span>
Pearson's chi2 analysis and Fisher's exact test were used to test for independence of the alleles (HWE) and for association analyses with patient and tumor characteristics, respectively. We allowed for three possible genetic models to explain differences in patient and tumor characteristics between genotype groups: linear, dominant or recessive effects. A linear effect, assuming a dose-response relationship of the association for the presence of zero, one or two copies of the allele, was tested using a (chi2) linear trend analysis [17]. A dominant effect between hetero- and homozygous combined carriers versus non-carriers was tested using chi2 analysis. Indications for recessive effects were not observed. Univariate and multivariate DFS analyses (endpoint: recurrence excluding second primary breast tumor) were carried out using Cox proportional hazards regression analysis. Hazard ratios (HRs) for the LHR insLQ and GnRH 16Ser alleles are presented with their 95% confidence interval (CI). Differences between HRs per LHR insLQ and GnRH 16Ser genotype were tested using the likelihood ratio test associated with the Cox regression analysis. In multivariate analysis, Cox proportional hazard models for DFS were applied to test the genotype variables against traditional factors using a forward stepwise model. The multivariate model included age, positive versus negative nodal status, differentiation grade, tumor size (larger tumors versus tumors </=2 cm), ER status and adjuvant therapy. DFS curves were generated using the actuarial method of Kaplan-Meier [18] and log-rank tests were used to test for equality of survival functions. All computations were carried out using the STATA statistical package, version 9.2 (Stata Corp., College Station, TX, USA). Statistical significance was assumed at P </= 0.05; P values are two-tailed and relate to data during the total period of follow-up.
###end p 28
###begin title 29
Results
###end title 29
###begin title 30
###xml 0 10 0 10 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LHR insLQ </italic>
###xml 14 29 14 29 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GnRH 16Trp/Ser </italic>
LHR insLQ and GnRH 16Trp/Ser genotyping
###end title 30
###begin p 31
###xml 26 36 26 36 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LHR insLQ </italic>
###xml 158 170 158 170 <italic xmlns:xlink="http://www.w3.org/1999/xlink">nonLQ/nonLQ </italic>
###xml 223 235 223 235 <italic xmlns:xlink="http://www.w3.org/1999/xlink">insLQ/insLQ </italic>
###xml 277 288 277 288 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GnRH 16Ser </italic>
###xml 353 365 353 365 <italic xmlns:xlink="http://www.w3.org/1999/xlink">16Trp/16Trp </italic>
###xml 418 430 418 430 <italic xmlns:xlink="http://www.w3.org/1999/xlink">16Ser/16Ser </italic>
###xml 483 485 483 485 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 496 498 496 498 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 614 616 614 616 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 709 719 709 719 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LHR insLQ </italic>
###xml 812 824 812 824 <italic xmlns:xlink="http://www.w3.org/1999/xlink">nonLQ/nonLQ </italic>
###xml 878 890 878 890 <italic xmlns:xlink="http://www.w3.org/1999/xlink">insLQ/insLQ </italic>
###xml 922 933 922 933 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GnRH 16Ser </italic>
###xml 1007 1019 1007 1019 <italic xmlns:xlink="http://www.w3.org/1999/xlink">16Trp/16Trp </italic>
###xml 1073 1085 1073 1085 <italic xmlns:xlink="http://www.w3.org/1999/xlink">16Ser/16Ser </italic>
###xml 1316 1326 1316 1326 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LHR insLQ </italic>
###xml 1330 1341 1330 1341 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GnRH 16Ser </italic>
###xml 74 82 <span type="species:ncbi:9606">patients</span>
Genotype analysis for the LHR insLQ polymorphism in the 278 premenopausal patients studied revealed an allele frequency of 0.27. This resulted in 147 (52.9%) nonLQ/nonLQ homozygotes, 113 (40.7%) heterozygotes and 18 (6.5%) insLQ/insLQ homozygotes. The allele frequency for the GnRH 16Ser polymorphism was 0.25. The genotype distribution was 157 (56.5%) 16Trp/16Trp homozygotes, 103 (37.1%) heterozygotes and 18 (6.5%) 16Ser/16Ser homozygotes. Both genotypes were found to be in HWE (P = 0.55 and P = 0.84, respectively). The genotype distributions and allele frequencies in the control cohort from the EPOS study (n = 1,758), did not differ significantly from the case distributions. Genotype results for the LHR insLQ polymorphism revealed an allele frequency of 0.29. The genotype distribution was 901 (51.3%) nonLQ/nonLQ homozygotes, 708 (40.3%) heterozygotes and 149 (8.5%) insLQ/insLQ homozygotes. Genotyping for the GnRH 16Ser allele resulted in an allele frequency of 0.25 and revealed 1,004 (57.1%) 16Trp/16Trp homozygotes, 627 (35.7%) heterozygotes and 127 (7.2%) 16Ser/16Ser homozygotes, in HWE. All genotype frequencies and allele frequencies are closely similar in the cases series and in the population controls, which lends support to the genotyping results in tumor material. We conclude that neither LHR insLQ nor GnRH 16Ser genotypes influence the risk of breast cancer development.
###end p 31
###begin title 32
###xml 18 25 <span type="species:ncbi:9606">patient</span>
Associations with patient and tumor characteristics
###end title 32
###begin p 33
###xml 68 83 68 83 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GnRH 16Trp/Ser </italic>
###xml 136 147 136 147 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GnRH 16Ser </italic>
###xml 171 182 171 182 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GnRH 16Ser </italic>
###xml 251 262 251 262 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GnRH 16Ser </italic>
###xml 337 339 337 339 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 355 360 355 360 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GnRH </italic>
###xml 419 421 419 421 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 430 440 430 440 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LHR insLQ </italic>
###xml 637 647 637 647 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LHR insLQ </italic>
###xml 651 662 651 662 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GnRH 16Ser </italic>
The distribution of clinico-pathological characteristics across the GnRH 16Trp/Ser genotype showed a dominant effect of presence of the GnRH 16Ser allele. Carriers of the GnRH 16Ser allele were, therefore, compared to non-carriers. Carriership of the GnRH 16Ser allele was significantly associated with increased lymph node involvement (P = 0.001), while GnRH genotype was associated with progesterone receptor levels (P = 0.02). LHR insLQ was associated with histological grade. Both polymorphisms were not significantly associated with other clinico-pathological characteristics. No significant interaction between the presence of the LHR insLQ and GnRH 16Ser variants was observed in these association analyses.
###end p 33
###begin title 34
###xml 16 26 16 26 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LHR insLQ </italic>
###xml 30 41 30 41 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GnRH 16Ser </italic>
Associations of LHR insLQ and GnRH 16Ser variants with DFS
###end title 34
###begin p 35
###xml 148 158 148 158 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LHR insLQ </italic>
###xml 283 285 283 285 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 300 301 300 301 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 340 350 340 350 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LHR insLQ </italic>
###xml 409 419 409 419 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LHR insLQ </italic>
###xml 487 489 485 487 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 518 520 510 512 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 537 539 529 531 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 601 612 593 604 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GnRH 16Ser </italic>
###xml 690 692 682 684 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 706 707 698 699 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 713 724 705 716 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GnRH 16Ser </italic>
###xml 208 216 <span type="species:ncbi:9606">patients</span>
###xml 327 335 <span type="species:ncbi:9606">patients</span>
We hypothesized that HPG-mediated increases in cumulative ovarian estrogen exposure influence breast cancer outcome. The adverse association of the LHR insLQ allele with DFS was observed in the premenopausal patients (HR for carriers versus non-carriers = 1.59, 95% CI 1.14 to 2.23, P = 0.007; Table 2). In these premenopausal patients the LHR insLQ genotype was an independent prognostic factor: addition of LHR insLQ carriership to the multivariate model resulted in an increase of chi2 from 44.06 to 52.23 (Deltachi2 = 8.17 (df = 1), P = 0.004) for DFS. The association between the presence of the GnRH 16Ser allele and DFS was also tested. An increased HR of 1.40 (95% CI 1.00 to 1.96, P = 0.05; Table 2) for GnRH 16Ser carriers versus non-carriers was observed.
###end p 35
###begin p 36
###xml 106 114 <span type="species:ncbi:9606">patients</span>
Cox univariate and multivariate analysis for disease free survival in the 278 premenopausal breast cancer patients
###end p 36
###begin p 37
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 87 89 87 89 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 163 164 163 164 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
###xml 178 189 178 189 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GnRH 16Ser </italic>
###xml 218 228 218 228 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LHR insLQ </italic>
###xml 8 16 <span type="species:ncbi:9606">patients</span>
###xml 249 257 <span type="species:ncbi:9606">patients</span>
aOf 120 patients who received adjuvant therapy, 110 received chemotherapy (mainly CMF, n = 101), 4 endocrine therapy, and 6 both; node negatives were not treated. bThe number of GnRH 16Ser non-carriers was 157, and of LHR insLQ non-carriers was 147 patients.
###end p 37
###begin p 38
###xml 111 113 111 113 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 131 141 131 141 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LHR insLQ </italic>
###xml 204 214 204 214 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LHR insLQ </italic>
###xml 302 304 302 304 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 372 382 372 382 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LHR insLQ </italic>
###xml 450 452 448 450 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 481 483 473 475 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 500 502 492 494 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 573 584 565 576 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GnRH 16Ser </italic>
###xml 667 669 659 661 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 708 719 700 711 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GnRH 16Ser </italic>
Interestingly, in the biological relevant hormone receptor subgroup (ER and/or progesterone receptor positive, n = 225 (81%)), the LHR insLQ genotype retained significance. The adverse association of the LHR insLQ allele with DFS had a HR for carriers versus non-carriers of 1.59 (95% CI 1.11 to 2.28, P = 0.012). It was also an independent prognostic factor: addition of LHR insLQ carriership to the multivariate model resulted in an increase of chi2 from 36.28 to 42.70 (Deltachi2 = 6.42 (df = 1), P = 0.01) for DFS. Moreover, the association between the presence of the GnRH 16Ser allele and DFS revealed a significantly increased HR of 1.44 (95% CI 1.01 to 2.07, P = 0.046). In multivariate analysis for GnRH 16Ser carriers versus non-carriers this was not significant.
###end p 38
###begin title 39
Cooperative effect of variants on the HPG axis and DFS
###end title 39
###begin p 40
###xml 231 242 231 242 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GnRH 16Ser </italic>
###xml 246 256 246 256 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LHR insLQ </italic>
###xml 432 443 432 443 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GnRH 16Ser </italic>
###xml 467 477 467 477 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LHR insLQ </italic>
###xml 36 41 <span type="species:ncbi:9606">woman</span>
###xml 302 310 <span type="species:ncbi:9606">patients</span>
The HPG system in the premenopausal woman involves a cooperative effect of both GnRH and LH action on the regulation of ovarian sex steroid production. Therefore, we have examined in an exploratory study the combined effect of the GnRH 16Ser and LHR insLQ variants in these premenopausal breast cancer patients. We combined heterozygous and homozygous carriers, providing four groups of similar sizes. Non-carriers, carriers of the GnRH 16Ser allele, carriers of the LHR insLQ allele, and carriers of both alleles were compared.
###end p 40
###begin p 41
###xml 188 190 188 190 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 223 225 223 225 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 241 243 241 243 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1a</xref>
###xml 254 255 254 255 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 346 348 346 348 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 591 593 585 587 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 610 612 604 606 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 653 655 647 649 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 719 729 713 723 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LHR insLQ </italic>
###xml 733 744 727 738 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GnRH 16Ser </italic>
###xml 64 72 <span type="species:ncbi:9606">patients</span>
The combination of both variants in premenopausal breast cancer patients, present in 22% of this group, resulted in a HR of 2.17 versus non-carriers of both variants (95% CI 1.36 to 3.48, P = 0.001; log-rank test for trend P = 0.001; Figure 1a and Table 2). This HR is higher than that for HER2 amplified tumors (HR of 1.61, 95% CI 1.09 to 2.39, P = 0.016); HER2 is amplified in about 20% of the tumors. In multivariate analysis, including the prognostic factors age, nodal status, differentiation grade, tumor size, ER status, and adjuvant therapy, the association was independent: Deltachi2 = 10.0 (df = 3), P = 0.018; HR = 2.14, 95% CI 1.32 to 3.45, P = 0.002. No significant interaction between the presence of the LHR insLQ and GnRH 16Ser variants was observed in these survival analyses.
###end p 41
###begin p 42
###xml 12 17 12 17 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GnRH </italic>
###xml 21 25 21 25 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LHR </italic>
###xml 67 71 67 71 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a) </bold>
###xml 247 257 247 257 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LHR insLQ </italic>
###xml 265 276 265 276 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GnRH 16Ser </italic>
###xml 365 369 365 369 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(b) </bold>
###xml 543 553 543 553 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LHR insLQ </italic>
###xml 561 572 561 572 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GnRH 16Ser </italic>
###xml 197 205 <span type="species:ncbi:9606">patients</span>
###xml 493 501 <span type="species:ncbi:9606">patients</span>
Relation of GnRH and LHR gene variants with disease-free survival. (a) Kaplan-Meier curves for disease free survival (DFS) comparing carriers versus non-carriers in all premenopausal breast cancer patients. DFS curves are depicted for carriers of LHR insLQ (blue), GnRH 16Ser (green) and both variants (red) versus non-carriers of both variants (gray dotted line). (b) Kaplan-Meier curves for DFS comparing carriers versus non-carriers in hormone receptor positive premenopausal breast cancer patients. DFS curves are depicted for carriers of LHR insLQ (blue), GnRH 16Ser (green) and both variants (red) versus non-carriers of both variants (gray dotted line).
###end p 42
###begin p 43
###xml 233 235 233 235 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 269 271 269 271 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 288 290 288 290 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1b</xref>
###xml 407 409 401 403 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 426 428 420 422 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 468 470 462 464 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 534 544 528 538 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LHR insLQ </italic>
###xml 548 559 542 553 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GnRH 16Ser </italic>
###xml 56 64 <span type="species:ncbi:9606">patients</span>
###xml 125 133 <span type="species:ncbi:9606">patients</span>
We next studied the effect in hormone receptor positive patients. The combination of both variants, present in 52 out of 225 patients of this group, resulted in a HR of 2.43 versus non-carriers of both variants (95% CI 1.42 to 4.18, P = 0.0013; log-rank test for trend P = 0.0055; Figure 1b). In multivariate analysis, including the prognostic factors listed above, the association was independent: Deltachi2 = 8.72 (df = 3), P = 0.03; HR = 2.06, 95% CI 1.21 to 3.49, P = 0.007. No significant interaction between the presence of the LHR insLQ and GnRH 16Ser variants was observed in these survival analyses.
###end p 43
###begin title 44
Discussion
###end title 44
###begin p 45
###xml 211 213 211 213 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 637 647 637 647 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LHR insLQ </italic>
###xml 758 763 758 763 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GnRH </italic>
###xml 777 787 777 787 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GnRH 16Ser</italic>
###xml 883 894 883 894 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GnRH 16Ser </italic>
###xml 898 908 898 908 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LHR insLQ </italic>
###xml 687 695 <span type="species:ncbi:9606">patients</span>
###xml 955 963 <span type="species:ncbi:9606">patients</span>
###xml 1072 1080 <span type="species:ncbi:9606">patients</span>
###xml 1130 1138 <span type="species:ncbi:9606">patients</span>
Breast cancer is a heterogeneous and complex disease. Many gene variants, acting in concert with each other and with environmental factors, may influence its susceptibility, prognosis and response to treatment [19]. In light of their possible role in the variability of estrogen exposure, variants of genes involved in the HPG axis are likely candidates to contribute to differences in clinical phenotype and outcome. In the present study we tested this hypothesis. In a genetic association approach we used stratification for ovarian activity and explored cooperative action of two HPG gene variants. We show an association between the LHR insLQ allele and shorter DFS in premenopausal patients, especially in the hormone receptor positive subset. A common GnRH gene variant, GnRH 16Ser, showed an association with lymph node involvement. In addition, coincident carriership of the GnRH 16Ser and LHR insLQ variants, present in almost one-quarter of the patients, resulted in a more than doubled risk of recurrence of disease in (hormone receptor positive) premenopausal patients with a long (>10 years follow-up of still living patients). Multivariate analyses showed that these associations with poor DFS were independent of known prognostic factors.
###end p 45
###begin p 46
###xml 24 29 24 29 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GnRH </italic>
###xml 201 210 201 210 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 285 287 285 287 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 452 462 452 462 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in silico </italic>
###xml 518 520 518 520 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 633 635 633 635 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 679 690 679 690 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GnRH 16Trp </italic>
###xml 1062 1073 1062 1073 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GnRH 16Ser </italic>
###xml 1528 1539 1528 1539 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GnRH 16Ser </italic>
###xml 1601 1606 1601 1606 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GnRH </italic>
###xml 820 825 <span type="species:ncbi:9606">women</span>
###xml 878 883 <span type="species:ncbi:9606">women</span>
###xml 1021 1029 <span type="species:ncbi:9606">patients</span>
Whether variants of the GnRH gene differ in function remains to be elucidated. Substitution of Trp16 by the less hydrophobic serine may change the efficiency of the GnRH signal peptide. Using the same in vitro assay for the insLQ signal peptide variant, as described by us previously [11], we were unable to detect a difference in signal peptide efficiency between the GnRH 16Ser and GnRH 16Trp signal peptide constructs (data not shown). Furthermore, in silico analysis of the variants using the program SignalP 3.0 [20] did not result in any difference in signal peptide characteristics. On the other hand, Iwasaki and colleagues [13] have described an association between the GnRH 16Trp allele and higher bone mineral density, considered to be an indirect marker for estrogen activity, in 384 Japanese postmenopausal women; this suggests there is higher estrogen activity in women bearing this variant. In contrast, we observed a significant increased lymph node involvement and shorter DFS in Caucasian breast cancer patients carrying the other variant, the GnRH 16Ser allele, which we hypothesize to result from a higher level of cumulative estrogen exposure. Possible reasons for the apparent conflicting results are numerous, including differences in sample size, technical approach, and ethnicity, or so far unknown differences in the interaction of genetic and environmental factors between Japanese and Caucasian subjects. Consequently, further studies are needed to identify the exact mechanisms of the effect of the GnRH 16Ser polymorphism, including linkage to other polymorphisms in the GnRH gene that may affect regulation of expression.
###end p 46
###begin p 47
###xml 39 44 39 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GnRH </italic>
###xml 48 52 48 52 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LHR </italic>
###xml 388 390 388 390 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 391 393 391 393 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 496 498 496 498 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 499 501 499 501 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 593 595 593 595 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 800 802 800 802 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 979 981 979 981 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 1146 1156 1146 1156 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LHR insLQ </italic>
###xml 1212 1220 <span type="species:ncbi:9606">patients</span>
There are several hypotheses as to how GnRH and LHR gene variants may affect tumor features and clinical outcome in breast cancer as demonstrated in this study. In view of the abundant data on the direct effects of GnRH modulation on sex steroid hormone-dependent cancers, a direct effect of locally produced GnRH via GnRH receptors expressed in breast cancer tissue cannot be ruled out [21-24]. Local co-expression of mRNAs for GnRH and the GnRH receptor in breast cancer tissue has been shown [25,26], and direct growth inhibition of cultured breast cancer cells have been reported as well [27]. However, to our knowledge, local production of GnRH has not been shown. Hypothalamic GnRH is unlikely to reach the breast via the peripheral circulation given its low concentration and short half-life [28]. Furthermore, the effects of GnRH agonist treatment regimens are most likely explained by down-regulation of pituitary GnRH receptors and subsequent shutdown of the HPG axis [29]. A few studies have shown LHR expression in normal and breast tumor cells. However, it is less likely that direct effects of LH explain the adverse association of LHR insLQ with DFS, since this was not seen in the postmenopausal patients (data not shown) in whom circulating LH levels are high.
###end p 47
###begin p 48
###xml 831 833 831 833 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 834 836 834 836 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 1052 1054 1052 1054 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 1125 1127 1125 1127 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 1287 1289 1287 1289 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 1584 1586 1584 1586 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 1764 1766 1764 1766 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 17 22 <span type="species:ncbi:9606">women</span>
###xml 492 497 <span type="species:ncbi:9606">women</span>
###xml 619 627 <span type="species:ncbi:9606">patients</span>
###xml 1349 1357 <span type="species:ncbi:9606">patients</span>
###xml 1533 1541 <span type="species:ncbi:9606">patients</span>
###xml 1786 1794 <span type="species:ncbi:9606">patients</span>
###xml 1891 1899 <span type="species:ncbi:9606">patients</span>
In premenopausal women, epithelial proliferation in the non-pregnant, non-lactating breast is maximal approximately one week after ovulation in the luteal phase of the menstrual cycle. During the luteal phase, which can be considered a risky period for carcinogenesis in the breast, the corpus luteum is the main site of estrogen and progesterone hormone production, which is, in large part, dependent on LHR action. Therefore, increased cyclic hormonal stimulation of early breast cancer in women carrying activating HPG gene variants may enhance dedifferentiation and worsen prognosis. In premenopausal breast cancer patients with advanced disease, reduction of estrogen levels by a GnRH agonist in combination with the ER antagonist tamoxifen improves clinical outcome compared with the use of GnRH agonists or tamoxifen alone [29,30]. Randomized trials assessing whether the combination of a GnRH agonist with an aromatase inhibitor as adjuvant therapy improves outcome compared to treatment consisting of a GnRH agonist and tamoxifen are ongoing [31]. Regimens for endocrine therapy are still largely empirically based [32]. Recently, it has been suggested that, as for adjuvant systemic therapy, the role of genetic factors in breast cancer treatment outcome should be considered [33]. Our current study identified almost 25% of premenopausal patients with a genetic background associated with clearly significant poor outcome and hypothetically associated with altered treatment outcomes. Exploratory studies in our subset of patients that received adjuvant endocrine therapy (n = 4) were too underpowered to detect differences in response. Finally, it can be hypothesized that the GnRH and LHR variants may play a role in chemotherapy-induced amennorhoea [33], since 110 of the patients studied were treated with chemotherapy. Although adjuvant chemotherapy was equally divided over patients with and without polymorphisms, possible differences in the chance of ovarian failure resulting from chemotherapy may bias the outcome. However, since chemotherapy is likely to inhibit ovarian activity, this is not anticipated.
###end p 48
###begin title 49
Conclusion
###end title 49
###begin p 50
###xml 153 163 153 163 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LHR insLQ </italic>
###xml 167 178 167 178 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GnRH 16Ser </italic>
###xml 501 511 501 511 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LHR insLQ </italic>
###xml 515 526 515 526 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GnRH 16Ser </italic>
###xml 138 143 <span type="species:ncbi:9606">women</span>
###xml 251 259 <span type="species:ncbi:9606">patients</span>
###xml 615 623 <span type="species:ncbi:9606">patients</span>
###xml 703 711 <span type="species:ncbi:9606">patients</span>
We have shown a strong and independent association with DFS (HR = 2.1) in almost one-quarter of (hormone receptor positive) premenopausal women carrying LHR insLQ and GnRH 16Ser genotypes. The observations strongly suggest that the adverse outcome in patients with these variants occurs through enhanced HPG-mediated ovarian estrogen production. Prospective studies, including serum estrogen analyses, are needed. When validated in independent studies, the observed results raise the possibility that LHR insLQ and GnRH 16Ser genotyping may provide additional prognostic information for premenopausal breast cancer patients in clinical practice and may result in tailored endocrine treatments for these patients.
###end p 50
###begin title 51
Abbreviations
###end title 51
###begin p 52
CI = confidence interval; df = degrees of freedom; DFS = disease free survival; ER = estrogen receptor; GnRH = gonadotropin-releasing hormone; HPG = hypothalamic-pituitary-gonadal; HR = hazard ratio; HWE = Hardy-Weinberg equilibrium; insLQ = insertion Leu-Gln; LH = luteinizing hormone; LHR = luteinizing hormone receptor; SNP = single nucleotide polymorphism.
###end p 52
###begin title 53
Competing interests
###end title 53
###begin p 54
The authors declare that they have no competing interests.
###end p 54
###begin title 55
Authors' contributions
###end title 55
###begin p 56
DP was involved in the acquisition of the data and drafted the manuscript. APNT and EMJJB conceived and supervised the experimental work and helped draft the manuscript. MPL carried out all statistical analysis. AGU was involved in the acquisition of the data and the drafting of the manuscript. JGMK and JAF initiated the breast tumor specimen collection program and participated in discussions on project design. HAPP reviewed the manuscript and added important intellectual content to it. All authors participated in subsequent revisions of the manuscript and approved its final version.
###end p 56
###begin title 57
Acknowledgements
###end title 57
###begin p 58
The authors wish to thank Miriam Verhoef-Post, Iris L van Staveren, Kirsten Ritstier and Pascal Arp for technical assistance in DNA preparation and genotyping, Fernando Rivadeneira for assistance in data interpretation and Drs Sleijfer, Bontenbal, Visser and Siemes and Prof. Stricker for constructive discussions.
###end p 58
###begin article-title 59
###xml 8 13 <span type="species:ncbi:9606">women</span>
###xml 71 76 <span type="species:ncbi:9606">women</span>
Younger women with breast carcinoma have a poorer prognosis than older women
###end article-title 59
###begin article-title 60
###xml 41 46 <span type="species:ncbi:9606">women</span>
Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer?
###end article-title 60
###begin article-title 61
###xml 45 50 <span type="species:ncbi:9606">women</span>
Adjuvant endocrine therapy for premenopausal women with early breast cancer
###end article-title 61
###begin article-title 62
SEER Cancer Statistics Review, 1975-2004
###end article-title 62
###begin article-title 63
Estrogen and the risk of breast cancer
###end article-title 63
###begin article-title 64
Molecular epidemiology of sporadic breast cancer. The role of polymorphic genes involved in oestrogen biosynthesis and metabolism
###end article-title 64
###begin article-title 65
Genetic and hormonal risk factors in breast cancer
###end article-title 65
###begin article-title 66
Menopause and hypothalamic-pituitary sensitivity to estrogen
###end article-title 66
###begin article-title 67
###xml 92 97 <span type="species:ncbi:9606">women</span>
Menopause transition: Annual changes in serum hormonal patterns over the menstrual cycle in women during a nine-year period prior to menopause
###end article-title 67
###begin article-title 68
Luteinizing hormone signaling and breast cancer: polymorphisms and age of onset
###end article-title 68
###begin article-title 69
###xml 166 174 <span type="species:ncbi:9606">patients</span>
A common polymorphism renders the luteinizing hormone receptor protein more active by improving signal peptide function and predicts adverse outcome in breast cancer patients
###end article-title 69
###begin article-title 70
Analysis of gonadotropin-releasing hormone gene structure in families with familial central precocious puberty and idiopathic hypogonadotropic hypogonadism
###end article-title 70
###begin article-title 71
Association of a Trp16Ser variation in the gonadotropin releasing hormone signal peptide with bone mineral density, revealed by SNP-dependent PCR typing
###end article-title 71
###begin article-title 72
###xml 67 72 <span type="species:ncbi:9606">women</span>
The prevalence of low bone mineral density in Dutch perimenopausal women: the Eindhoven perimenopausal osteoporosis study
###end article-title 72
###begin article-title 73
###xml 17 22 <span type="species:ncbi:9606">human</span>
Structure of the human luteinizing hormone-choriogonadotropin receptor gene: unusual promoter and 5' non-coding regions
###end article-title 73
###begin article-title 74
Applied Biosystems
###end article-title 74
###begin article-title 75
From genotypes to genes: doubling the sample size
###end article-title 75
###begin article-title 76
Nonparametric estimation from incomplete observations
###end article-title 76
###begin article-title 77
###xml 41 46 <span type="species:ncbi:9606">human</span>
Approaches to identify genes for complex human diseases: lessons from Mendelian disorders
###end article-title 77
###begin article-title 78
SignalP
###end article-title 78
###begin article-title 79
###xml 124 129 <span type="species:ncbi:9606">human</span>
Luteinizing hormone-releasing hormone agonist triptorelin and antagonist cetrorelix inhibit EGF-induced c-fos expression in human gynecological cancers
###end article-title 79
###begin article-title 80
Gonadotropin releasing hormone receptor expression in primary breast cancer: comparison of immunohistochemical, radioligand and western blot analyses
###end article-title 80
###begin article-title 81
Signalling, cycling and desensitisation of gonadotrophin-releasing hormone receptors
###end article-title 81
###begin article-title 82
###xml 121 126 <span type="species:ncbi:9606">human</span>
Induction of apoptosis by AN-152, a cytotoxic analog of luteinizing hormone-releasing hormone (LHRH), in LHRH-R positive human breast cancer cells is independent of multidrug resistance-1 (MDR-1) system
###end article-title 82
###begin article-title 83
###xml 79 84 <span type="species:ncbi:9606">human</span>
The genes for gonadotropin-releasing hormone and its receptor are expressed in human breast with fibrocystic disease and cancer
###end article-title 83
###begin article-title 84
###xml 68 73 <span type="species:ncbi:9606">human</span>
Two forms of gonadotropin-releasing hormone (GnRH) are expressed in human breast tissue and overexpressed in breast cancer: a putative mechanism for the antiproliferative effect of GnRH by down-regulation of acidic ribosomal phosphoproteins P1 and P2
###end article-title 84
###begin article-title 85
###xml 10 15 <span type="species:ncbi:9606">human</span>
Growth of human breast cancer cells inhibited by a luteinizing hormone-releasing hormone agonist
###end article-title 85
###begin article-title 86
###xml 125 133 <span type="species:ncbi:9606">patients</span>
Metabolic clearance and plasma half disappearance time of exogenous gonadotropin releasing hormone in normal subjects and in patients with liver disease and chronic renal failure
###end article-title 86
###begin article-title 87
Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials
###end article-title 87
###begin article-title 88
Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer: a randomized study
###end article-title 88
###begin article-title 89
###xml 99 106 <span type="species:ncbi:9606">patient</span>
Trends in endocrine therapy and chemotherapy for early breast cancer: a focus on the premenopausal patient
###end article-title 89
###begin article-title 90
Breast cancer: achievements in adjuvant systemic therapies in the pre-genomic era
###end article-title 90
###begin article-title 91
Breast cancer treatment and ovarian failure: risk factors and emerging genetic determinants
###end article-title 91

